BioLineRx Ltd. (TLV:BLRX)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
2.000
+0.200 (11.11%)
May 4, 2025, 3:49 PM IDT
-88.02%
Market Cap 40.19M
Revenue (ttm) 105.41M
Net Income (ttm) -33.59M
Shares Out 2.23B
EPS (ttm) -0.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,817,266
Average Volume 5,452,833
Open 1.900
Previous Close 1.800
Day's Range 1.900 - 2.000
52-Week Range 1.400 - 20.800
Beta 0.86
RSI 47.46
Earnings Date May 25, 2025

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin les... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 28
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol BLRX
Full Company Profile

Financial Performance

In 2024, BioLineRx's revenue was $28.94 million, an increase of 502.92% compared to the previous year's $4.80 million. Losses were -$9.22 million, -84.79% less than in 2023.

Financial numbers in USD Financial Statements

News

BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript

BioLineRx Ltd. (NASDAQ:BLRX) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Irina Koffler - IR, LifeSci Advisors Phil Serlin - CEO Mali Zeevi - CFO Ella Sorani - Chie...

4 weeks ago - Seeking Alpha

BioLineRx Reports 2024 Financial Results and Provides Corporate Update

- Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases - - Executed license agreement with Ayrmid Pharma Ltd. f...

4 weeks ago - PRNewsWire

BioLineRx Q4 2024 Earnings Preview

5 weeks ago - Seeking Alpha

Uncovering Potential: BioLine Rx's Earnings Preview

BioLine Rx (NASDAQ: BLRX) will release its quarterly earnings report on Monday, 2025-03-31. Here's a brief overview for investors ahead of the announcement. Analysts anticipate BioLine Rx to report a...

5 weeks ago - Benzinga

BioLineRx to Report 2024 Annual Results on March 31, 2025

Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , March 24, 2025 /PRNewswire/ -- BioLineRx Ltd.

5 weeks ago - PRNewsWire

BioLineRx Issues Letter to Shareholders

- Company outlines strategic long-term vision and financial outlook - TEL AVIV, Israel , Jan. 21, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical co...

3 months ago - PRNewsWire

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares

TEL AVIV, Israel , Jan. 17, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, ...

3 months ago - PRNewsWire

Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

Shares of Taiwan Semiconductor Manufacturing Company Limited (NYSE: TSM) rose sharply in today's pre-market trading after the company announced fourth-quarter results . Taiwan Semiconductor Mfg. said...

3 months ago - Benzinga

Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite jumping more than 200 points on Monday. The Dow traded up 0.08% to 42,765.84 while the NASDAQ gained 1.05% to 19,828.63. ...

4 months ago - Benzinga

Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite jumping more than 200 points on Monday.

4 months ago - Benzinga

BioLineRx Announces $10 Million Registered Direct Offering

TEL AVIV, Israel , Jan. 6, 2025 /PRNewswire/ -- BioLineRx Ltd. (Nasdaq: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a development stage biopharmaceutical company pursuing life-changing therapie...

4 months ago - PRNewsWire

BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript

BioLineRx Ltd. (NASDAQ:BLRX) Q3 2024 Earnings Conference Call November 25, 2024 8:30 AM ETCompany ParticipantsJohn Lacey - Head of IR & Corporate...

5 months ago - Seeking Alpha

BioLineRx GAAP EPS of $0.00 beats by $0.07, revenue of $4.94M misses by $0.35M

BioLineRx press release (BLRX): Q3 GAAP EPS of $0.00 beats by $0.07. Revenue of $4.94M misses by $0.35M. As of September 30, 2024, the company had cash,

5 months ago - Seeking Alpha

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

- Executed license agreement with Ayrmid Ltd. for APHEXDA ® (motixafortide) for $10 million upfront, up to $87 million in commercial milestones, and 18-23% tiered royalties on sales - - Received $9 mi...

5 months ago - PRNewsWire

Earnings Scheduled For November 25, 2024

Companies Reporting Before The Bell • Alarum Technologies (NASDAQ: ALAR) is likely to report quarterly earnings at $0.04 per share on revenue of $7.00 million. • BioLine Rx (NASDAQ: BLRX) is expecte...

5 months ago - Benzinga

BioLineRx Q3 2024 Earnings Preview

BioLineRx (BLRX) is set to report Q3 earnings on Nov 25. Consensus estimates are -$0.11 EPS and $5.29M revenue.

5 months ago - Seeking Alpha

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

– BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% ...

5 months ago - PRNewsWire

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel , Nov. 20, 2024 /PRNewswire/ -- BioLineRx Ltd.

5 months ago - PRNewsWire

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

- Findings suggest motixafortide alone, and in combination with natalizumab, could support the collection of the large number of stem cells required by gene therapies for sickle cell disease within a ...

6 months ago - PRNewsWire

BioLineRx receives USPTO allowance of new composition of matter patent on motixafortide

BioLineRx receives patent allowance for motixafortide in the U.S., extending intellectual property protection through December 2041.

7 months ago - Seeking Alpha

BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

– Allowance strengthens company's intellectual property estate and extends motixafortide patent protection in the U.S. through December 2041 – TEL AVIV, Israel , Oct. 16, 2024 /PRNewswire/ -- BioLineR...

7 months ago - PRNewsWire